Yeah for sure, not suggesting for a second that ANP aren’t intending to compete with or out perform existing therapies available for DMD. My point is that their therapeutic approach is one of a couple that companies have taken to treat DMD. So far as I have seen, AT1102 appears to be the most effective and generalised treatment to date, however I welcome people to provide insights into therapies offered by those other than ANP and Sarepta.
Comparison Capricor vs. ANP, page-25
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.8¢ |
Change
-0.002(2.50%) |
Mkt cap ! $70.32M | |||
| Open | High | Low | Value | Volume |
| 7.6¢ | 7.8¢ | 7.5¢ | $32.58K | 429.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 253224 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 253231 | 2 |
View Market Depth
| Last trade - 14.56pm 22/07/2024 (20 minute delay) ? |
| PER (ASX) Chart |